Literature DB >> 18347934

Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.

László Herszényi1, Ferenc Sipos, Orsolya Galamb, Norbert Solymosi, István Hritz, Pál Miheller, Lajos Berczi, Béla Molnár, Zsolt Tulassay.   

Abstract

It has been proposed that matrix metalloproteinases (MMPs) play a role in tumor invasion. We determined protein expression of matrix metalloproteinase-9 (MMP-9) in colorectal cancer (CRC), corresponding normal mucosa and colorectal adenomas. For confirmation of immunohistochemical results MMP-9 TaqMan RT-PCR analysis was performed. Expression of MMP-9 was determined on paraffin embedded biopsy sections by immunohistochemistry in 31 CRC patients (from cancer tissue and corresponding normal mucosa) and in 30 patients with adenoma (nine adenomas with high grade of dysplasia). MMP-9 immunostaining was determined semi-quantitatively. For Taqman RT-PCR analyses normal mucosa (n = 5), adenoma without (n = 6) and with high grade dysplasia (n = 7) and CRC (n = 10) were investigated. Statistical analysis with ANOVA, LSD test and correlation analysis were performed. P value of <0.05 was considered significant. The MMP-9 expression in CRC was significantly higher compared to adenomas or the normal mucosa (P = 0.001). Significantly higher expression of MMP-9 has been observed in adenomas with high grade dysplasia compared to other adenomas or normal colon (P < 0.001). Diffuse strong MMP-9 expression was present in tumor as well as in stromal cells. In adenoma samples, dysplastic epithelial cells showed moderate intensive cytoplasmic MMP-9 expression, with a clear-cut differentiation between dysplastic and non-dysplastic areas. Staining intensity correlated with the grade of CRC. We demonstrate a significantly higher expression of MMP-9 in adenoma with high grade dysplasia-CRC sequence as compared to normal tissue. The over-expression of MMP-9 strongly suggests its association with colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347934     DOI: 10.1007/s12253-008-9004-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  61 in total

Review 1.  Extracellular matrix remodelling: the role of matrix metalloproteinases.

Authors:  Ivan Stamenkovic
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

2.  Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.

Authors:  Q Gao; M J W Meijer; F J G M Kubben; C F M Sier; L Kruidenier; W van Duijn; M van den Berg; R A van Hogezand; C B H W Lamers; H W Verspaget
Journal:  Dig Liver Dis       Date:  2005-08       Impact factor: 4.088

3.  Location and age at onset of colorectal cancer in Hungarian patients between 1993 and 2004. The high number of advanced cases supports the need for a colorectal cancer screening program in Hungary.

Authors:  Peter Fuszek; Henrik Csaba Horvath; Gabor Speer; Janos Papp; Petra Haller; Simon Fischer; Judit Halasz; Balazs Jaray; Eszter Szekely; Zsuzsanna Schaff; Andras Papp; Attila Bursics; Laszlo Harsanyi; Peter Lukovich; Peter Kupcsulik; Erika Hitre; Peter Laszlo Lakatos
Journal:  Anticancer Res       Date:  2006 Jan-Feb       Impact factor: 2.480

4.  Cysteine and serine proteases in gastric cancer.

Authors:  M Plebani; L Herszènyi; R Cardin; G Roveroni; P Carraro; M D Paoli; M Rugge; W F Grigioni; D Nitti; R Naccarato
Journal:  Cancer       Date:  1995-08-01       Impact factor: 6.860

5.  Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.

Authors:  E A Baker; F G Bergin; D J Leaper
Journal:  Br J Surg       Date:  2000-09       Impact factor: 6.939

6.  Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis.

Authors:  K Saito; S Takeha; K Shiba; S Matsuno; T Sorsa; H Nagura; H Ohtani
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

7.  Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.

Authors:  C Frederiksen; J Lykke; Ib J Christensen; N Brünner; H J Nielsen
Journal:  Scand J Clin Lab Invest       Date:  2007       Impact factor: 1.713

8.  Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas.

Authors:  Yoshito Matsuyama; Sonshin Takao; Takashi Aikou
Journal:  J Surg Oncol       Date:  2002-06       Impact factor: 3.454

9.  Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism.

Authors:  David Murray; Mary Morrin; Susan McDonnell
Journal:  Anticancer Res       Date:  2004 Mar-Apr       Impact factor: 2.480

10.  Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer.

Authors:  E T Waas; R M L M Lomme; J DeGroot; Th Wobbes; T Hendriks
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more
  19 in total

1.  Active matrix metalloproteinase-2 activity discriminates colonic mucosa, adenomas with and without high-grade dysplasia, and cancers.

Authors:  Mary Jo Murnane; Jinguo Cai; Sania Shuja; David McAneny; John B Willett
Journal:  Hum Pathol       Date:  2011-01-15       Impact factor: 3.466

2.  The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis.

Authors:  Gábor Lakatos; Ferenc Sipos; Pál Miheller; István Hritz; Mária Zsófia Varga; Márk Juhász; Béla Molnár; Zsolt Tulassay; László Herszényi
Journal:  Pathol Oncol Res       Date:  2011-06-16       Impact factor: 3.201

3.  High expression of osteoglycin decreases gelatinase activity of murine hepatocarcinoma Hca-F cells.

Authors:  Xiao-Nan Cui; Jian-Wu Tang; Bo Song; Bo Wang; Shan-Yan Chen; Li Hou
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

4.  Near-infrared fluorescence imaging using a protease-specific probe for the detection of colon tumors.

Authors:  Soon Man Yoon; Seung-Jae Myung; Byong Duk Ye; In-Wha Kim; Nam Gon Lee; Yeon Mi Ryu; Kyeongsoon Park; Kwangmeyung Kim; Ick Chan Kwon; Young Soo Park; Chan-Sik Park; Dae Hyuk Moon; Do Hoon Kim; Mi Young Do; Jeong-Sik Byeon; Suk-Kyun Yang; Jin-Ho Kim
Journal:  Gut Liver       Date:  2010-12-17       Impact factor: 4.519

5.  Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer.

Authors:  Vesna V Dragutinović; Nevena V Radonjić; Nataša D Petronijević; Svetislav B Tatić; Ivan B Dimitrijević; Nebojša S Radovanović; Zoran V Krivokapić
Journal:  Mol Cell Biochem       Date:  2011-05-04       Impact factor: 3.396

6.  The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.

Authors:  Barbara Mroczko; Magdalena Groblewska; Bogna Okulczyk; Bogusław Kedra; Maciej Szmitkowski
Journal:  Int J Colorectal Dis       Date:  2010-06-17       Impact factor: 2.571

7.  Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma.

Authors:  Abdelbaset Buhmeida; Riyad Bendardaf; Marja Hilska; Yrjö Collan; Matti Laato; Stina Syrjänen; Kari Syrjänen; Seppo Pyrhönen
Journal:  J Gastrointest Cancer       Date:  2009

Review 8.  Prognostic value of innate and adaptive immunity in colorectal cancer.

Authors:  Fabio Grizzi; Paolo Bianchi; Alberto Malesci; Luigi Laghi
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

9.  Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse.

Authors:  Mark J Sinnamon; Kathy J Carter; Barbara Fingleton; Lynn M Matrisian
Journal:  Int J Exp Pathol       Date:  2008-12       Impact factor: 1.925

10.  Measuring the combinatorial expression of solute transporters and metalloproteinases transcripts in colorectal cancer.

Authors:  Caroline A Kerr; Robert Dunne; Barney M Hines; Michelle Zucker; Leah Cosgrove; Andrew Ruszkiewicz; Trevor Lockett; Richard Head
Journal:  BMC Res Notes       Date:  2009-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.